Evidence map›Paper›PMID 34209378›Full record

ArticleCells2021

Infusion of Phagocytic Macrophages Overexpressing CPT1a Ameliorates Kidney Fibrosis in the UUO Model.

Priscila Calle, Soraya Játiva, Selene Torrico, Angeles Muñoz, Miriam García, Anna Sola, Dolors Serra, Paula Mera, Laura Herrero, Georgina Hotter

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Development of Cell Therapies for Renal Disease and Regenerative Medicine.International journal of molecular sciences · 2022
    Review
  8. Article
  9. [Establishment of an Animal Model of Vesicoureteral Reflux Renal Injury through Partial Bladder Outlet Obstruction].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Priscila CalleM2rlab-XCELL, 28010 Madrid, Spain.ORCID 0000-0001-9872-8013
Soraya JátivaM2rlab-XCELL, 28010 Madrid, Spain.
Selene TorricoM2rlab-XCELL, 28010 Madrid, Spain.
Angeles MuñozDepartment of Experimental Pathology, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas Institut d'Investigacions Biomèdiques August Pi i Sunyer (IIBB-CSIC-IDIBAPS), 08036 Barcelona, Spain.
Miriam GarcíaM2rlab-XCELL, 28010 Madrid, Spain.
Anna SolaDepartment of Experimental Nephrology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet del Llobregat, 08908 Barcelona, Spain.
Dolors SerraCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029 Madrid, Spain.ORCID 0000-0003-2379-9313
Paula MeraCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029 Madrid, Spain.ORCID 0000-0002-4936-4206
Laura HerreroCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029 Madrid, Spain.ORCID 0000-0003-4244-4673
Georgina HotterDepartment of Experimental Pathology, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas Institut d'Investigacions Biomèdiques August Pi i Sunyer (IIBB-CSIC-IDIBAPS), 08036 Barcelona, Spain.
Consejo Superior de Investigaciones Científicas · ESInstituto de Salud Carlos III · ESInstitut d'Investigació Biomédica de Bellvitge · ES

Funding

Fondo de Investigación Sanitaria (FIS) PI20/00900Ministerio de Economía, Industria y Competitividad, Gobierno de España SAF2015-67770-R
6 · The paper itself

Abstract

Phagocytosis is an inherent function of tissue macrophages for the removal of apoptotic cells and cellular debris during acute and chronic injury; however, the dynamics of this event during fibrosis development is unknown. We aim to prove that during the development of kidney fibrosis in the unilateral ureteral obstruction (UUO) model, there are some populations of macrophage with a reduced ability to phagocytose, and whether the infusion of a population of phagocytic macrophages could reduce fibrosis in the murine model UUO. For this purpose, we have identified the macrophage populations during the development of fibrosis and have characterized their phagocytic ability and their expression of CPT1a. Furthermore, we have evaluated the therapeutic effect of macrophages overexpressing CPT1a with high phagocytic skills. We evidenced that the macrophage population which exhibits high phagocytic ability (F4/80low-CD11b) in fibrotic animals decreases during the progression of fibrosis while the macrophage population with lower phagocytic ability (F4/80high-CD11b) in fibrotic conditions, conversely, increases and CPT1a macrophage cell therapy with a strengthening phagocytic ability is associated with a therapeutic effect on kidney fibrosis. We have developed a therapeutic approach to reduce fibrosis in the UUO model by enrichment of the kidney resident macrophage population with a higher proportion of exogenous phagocytic macrophages overexpressing CPT1a.

Indexed as

PhagocytosisAnimalsCarnitine O-PalmitoyltransferaseCD11b AntigenCell- and Tissue-Based TherapyDisease Models, AnimalDisease ProgressionFibrosisGene Expression ProfilingKidneyMacrophagesMaleMiceRAW 264.7 CellsUreteral ObstructionCarnitine O-PalmitoyltransferaseCD11b AntigenCPT1B protein, mouseCPT1akidney fibrosismacrophagephagocytosis

Identifiers

PMID34209378
PMCPMC8304788
OpenAlexW3175641907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.